News | May 16, 2025
JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Branded formulation business continues to perform well across domestic and export markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
